GSK3β/eEF2K信号通路对小鼠肺纤维化过程的影响*

目的: 探讨糖原合成酶激酶-3(GSK3β)/真核延伸因子激酶2(eEF2K)信号通路对肺纤维化进程的影响,为临床治疗肺纤维化寻找新的思路。方法: 采用一次性气管注射法构建C57BL/6雄性小鼠博莱霉素肺纤维化模型,造模14 d后将动物分成模型组、阴性抑制组与抑制组(n=5),另设空白组不作处理。抑制组使用腹腔注射TDZD-8(4 mg/kg),阴性抑制组腹腔注射二甲基亚砜(DMSO)溶液,28 d后处死采集指标。采用苏木精-伊红染色法检测小鼠肺脏病变情况;试剂盒水解法检测肺组织中羟脯氨酸(Hyp)的含量;采用Western blot法检测肺脏中GSK3β、磷酸化GSK3β(p-GSK3β)、eEF2K、p-eEF2K(Ser70)、p-eEF2K(Ser392)、p-eEF2K(Ser470)、基质金属蛋白酶-2前体蛋白(pro-MMP-2)、基质金属蛋白酶-2(MMP-2)蛋白表达水平,使用免疫组织化学法检测肺脏中MMP-2、胶原蛋白I(Col I)、胶原蛋白Ⅲ(Col Ⅲ)、α-平滑肌蛋白(α-SMA)的表达。结果: 与空白组相比,模型组中GSK3β、p-GSK3β、p-eEF2K(Ser70)、p-eEF2K(Ser392)、p-eEF2K(Ser470)、pro-MMP-2、MMP-2、Col I、Col Ⅲ、α-SMA蛋白表达水平升高,eEF2K蛋白表达水平降低(P＜0.05);与模型组相比,抑制组GSK3β、p-GSK3β、p-eEF2K(Ser70)、p-eEF2K(Ser392)、p-eEF2K(Ser470)、pro-MMP-2、MMP-2、Col I、Col Ⅲ、α-SMA蛋白表达降低,eEF2K蛋白表达升高(P＜ 0.05)。结论: GSK3β能通过Ser70、Ser392、Ser470这3个位点磷酸化激活eEF2K,增加纤维化指标含量,促进肺纤维化形成,加重肺组织病变。     

Biophysical and Structural Characterization of Novel RAS-Binding Domains (RBDs) of PI3Kα and PI3Kγ

Phosphatidylinositol-3-kinases (PI3Ks) are lipid kinases that phosphorylate phosphatidylinositol 4,5-bisphosphate to generate a key lipid second messenger, phosphatidylinositol 3,4,5-bisphosphate. PI3Kα and PI3Kγ require activation by RAS proteins to stimulate signaling pathways that control cellular growth, differentiation, motility and survival. Intriguingly, RAS binding to PI3K isoforms likely differ, as RAS mutations have been identified that discriminate between PI3Kα and PI3Kγ, consistent with low sequence homology (23%) between their RAS binding domains (RBDs). As disruption of the RAS/PI3Kα interaction reduces tumor growth in mice with RAS- and epidermal growth factor receptor driven skin and lung cancers, compounds that interfere with this key interaction may prove useful as anti-cancer agents. However, a structure of PI3Kα bound to RAS is lacking, limiting drug discovery efforts. Expression of full-length PI3K isoforms in insect cells has resulted in low yield and variable activity, limiting biophysical and structural studies of RAS/PI3K interactions. This led us to generate the first RBDs from PI3Kα and PI3Kγ that can be expressed at high yield in bacteria and bind to RAS with similar affinity to full-length PI3K. We also solved a 2.31 Å X-ray crystal structure of the PI3Kα-RBD, which aligns well to full-length PI3Kα. Structural differences between the PI3Kα and PI3Kγ RBDs are consistent with differences in thermal stability and may underly differential RAS recognition and RAS-mediated PI3K activation. These high expression, functional PI3K RBDs will aid in interrogating RAS interactions and could aid in identifying inhibitors of this key interaction.     

敲低去泛素化酶USP13抑制K562细胞的增殖*

目的:研究去泛素化酶USP13对人慢性髓系白血病细胞系K562增殖和凋亡的影响,并进行初步的机制探究。方法:构建pLKO.1-shUSP13-GFP慢病毒干涉载体,慢病毒包装后感染并建立稳定敲低USP13的K562细胞株。免疫印迹检测K562细胞中USP13蛋白的敲低效率。流式细胞术分析敲低USP13对K562细胞增殖和凋亡的影响。免疫共沉淀和蛋白质泛素化实验探究USP13调控K562细胞的分子机制。结果:成功构建pLKO.1-shUSP13-GFP慢病毒干涉载体,同时利用慢病毒体系获得稳定敲低USP13的K562细胞株。流式细胞术结果显示,敲低USP13促进K562细胞凋亡、抑制细胞增殖。分子机制研究发现,敲低USP13通过增强c-Myc泛素化进而导致其蛋白质水平降低。结论:初步揭示了USP13调控K562细胞增殖和凋亡的分子机制,为治疗慢性髓系白血病提供了潜在的靶点。     

AZD8835 inhibits osteoclastogenesis and periodontitis-induced alveolar bone loss in rats

Chronic periodontitis (CP) is one of the most common oral diseases, which is characterized by the loss of connective tissue and alveolar bone in adults. AZD8835, a novel dual phosphoinositide-3-kinase (PI3K) inhibitor, is currently in phase 1 clinical evaluation to treat breast cancer. However, whether AZD8835 has any effect on teeth and alveolar bone health remains unclear. In the current study, we aimed to investigate the potential effect of AZD8835 in treating CP in vitro and in vivo. We found that AZD8835 could inhibit osteoclast differentiation, bone resorption, and downregulate the expression of osteoclast marker genes, such as tartrate-resistant acid phosphatase (Trap), cathepsin K (Ctsk), V-ATPase d2 (Atp6v0d2), and calcitonin receptor (Ctr). In addition, AZD8835 suppressed osteoclastogenesis by inhibiting receptor activator of nuclear factor kappa B ligand (RANKL)-induced PI3K/protein kinase B (AKT), extracellular signal-regulated kinase, and nuclear factor-κB signaling in BMMs. In vivo, AZD8835 greatly ameliorated alveolar bone (ABL) loss in rats with CP. Meanwhile, histological examination showed fewer osteoclasts in the treatment group. In conclusion, these results indicated that AZD8835 is a promising agent to reduce ABL in CP.     

Pristimerin Induces Autophagy‐Mediated Cell Death in K562 Cells through the ROS/JNK Signaling Pathway

Chronic myeloid leukemia (CML) is a lethal malignancy, and the progress toward long‐term survival has stagnated in recent decades. Pristimerin, a quinone methide triterpenoid isolated from the Celastraceae and Hippocrateaceae families, is well‐known to exert potential anticancer activities. In this study, we investigated the effects and the mechanisms of action on CML. We found that pristimerin inhibited cell proliferation of K562 CML cells by causing G1 phase arrest. Furthermore, we demonstrated that pristimerin triggered autophagy and apoptosis. Intriguingly, pristimerin‐induced cell death was restored by an autophagy inhibitor, suggesting that autophagy is cross‐linked with pristimerin‐induced apoptosis. Further studies revealed that pristimerin could produce excessive reactive oxygen species (ROS), which then induce JNK activation. These findings provide clear evidence that pristimerin might be clinical benefit to patients with CML.     

Linc01014 regulates gefitinib resistance in oesophagus cancer via EGFR‐PI3K‐AKT‐mTOR signalling pathway

This study aimed to explore the underlying mechanism of linc01014 in oesophagus cancer gefitinib resistance. Gefitinib‐resistant oesophagus squamous cell carcinoma (ESCC gefitinibR) cell lines were constructed by using different gefitinib treatment in FLO‐1, KYAE‐1, TE‐8 and TE‐5 cell lines and confirmed by MTS50 and proliferation assays. Expression of linc01014 was overexpressed/silenced in FLO‐1 cells followed by gefitinib treatment, and then, the apoptosis‐associated markers Bax and Bcl‐2, and PI3KCA in PI3K signalling pathway were determined using Western blotting. MST50 and morphology analyses showed that ESCC gefitinibR cell lines presented obvious gefitinib resistance than their parental ESCC cell lines. ESCC gefitinibR cell lines showed significantly higher proliferation abilities than their parental ESCC cell lines after treating with gefitinib. Overexpression of linc01014 significantly inhibited the apoptosis of FLO‐1 cells induced by gefitinib and silencing linc01014 obviously promoted the apoptosis of FLO‐1 cells induced by gefitinib. Silencing linc01014 could significantly increase the gefitinib chemotherapy sensitivity of oesophagus cancer via PI3K‐AKT‐mTOR signalling pathway.     

NaHCO3胁迫下3种灌木Na+、K+、Ca2+的吸收及转运

通过盆栽试验,采用原子吸收分光光度法和非损伤微测技术,研究了NaHCO₃胁迫(300 mmol·L^-1)对大洋洲滨藜、四翅滨藜和宁夏枸杞3种灌木离子吸收及运转的影响.结果表明: 随着NaHCO₃浓度升高,两种滨藜和宁夏枸杞叶片中Na⁺含量升高,300 mmol·L^-1NaHCO₃胁迫下,宁夏枸杞叶肉细胞Na⁺的外排增加,两种滨藜净Na⁺外排降低;随着胁迫时间的延长,大洋洲滨藜和宁夏枸杞叶片的K⁺含量下降,Na⁺/K⁺升高,四翅滨藜叶片K⁺含量升高,Na⁺/K⁺降低;随着浓度的升高,宁夏枸杞叶片积累Ca²⁺减少,Na⁺/Ca²⁺高于对照,叶肉细胞Ca²⁺外排;两种滨藜叶Ca²⁺含量总体呈升高趋势,叶肉细胞Ca²⁺表现为内流.在NaHCO₃胁迫下,3种灌木通过不同的策略来消除Na⁺毒害.宁夏枸杞叶片Na⁺的积累抑制了对Ca²⁺的吸收;两种滨藜Ca²⁺的内流促使细胞质中游离Ca²⁺增加,增加的细胞质\[Ca²⁺\]cyt防治质膜H⁺ ATPase去极化,限制K⁺的外排,从而维持细胞内Na⁺/K⁺的平衡,其中四翅滨藜调控Na⁺/K⁺平衡的能力较强.     

ATP1B3 Protein Modulates the Restriction of HIV-1 Production and Nuclear Factor κ Light Chain Enhancer of Activated B Cells (NF-κB) Activation by BST-2

Here, we identify ATP1B3 and fibrillin-1 as novel BST-2-binding proteins. ATP1B3 depletion in HeLa cells (BST-2-positive cells), but not 293T cells (BST-2-negative cells), induced the restriction of HIV-1 production in a BST-2-dependent manner. In contrast, fibrillin-1 knockdown reduced HIV-1 production in 293T and HeLa cells in a BST-2-independent manner. Moreover, NF-κB activation was enhanced by siATP1B3 treatment in HIV-1- and HIV-1ΔVpu-infected HeLa cells. In addition, ATP1B3 silencing induced high level BST-2 expression on the surface of HeLa cells. These results indicate that ATP1B3 is a co-factor that accelerates BST-2 degradation and reduces BST-2-mediated restriction of HIV-1 production and NF-κB activation.